Note 15 - Commitments and Contingencies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands							1 Months Ended							12 Months Ended
	Aug. 31, 2024	Aug. 30, 2024	Sep. 13, 2022	Oct. 28, 2021	Jun. 15, 2021	Mar. 26, 2020	Dec. 31, 2024	Aug. 31, 2024	Mar. 31, 2024	Nov. 30, 2023	Oct. 31, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Nov. 30, 2024	Sep. 30, 2024	Mar. 14, 2023	Nov. 30, 2022	Dec. 31, 2021	Mar. 27, 2020
Stock Issued During Period, Value, New Issues														$ 7,000
Share Price (in dollars per share)							$ 3.22							$ 3.22	$ 2.32	$ 2.32		$ 6
Research and Development Expense, Total														$ 3,255	$ 3,322	$ 3,996
Cost of Goods and Services Sold														$ 15,600	10,581	6,933
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)														583,334
Stock Issued During Period, Value, New Issues														$ 1
Share Price (in dollars per share)						$ 3.33
License [Member]
Cost of Goods and Services Sold														$ 270	1,000	$ 1,640
Carglumic Acid Tablets [Member]
Payments to Acquire Marketing Rights				$ 3,250
Commitment, Allocation of Profits, Percentage				50.00%
Betaine Anhydrous [Member]
Payments to Acquire Marketing Rights			$ 2,000							$ 125
Commitment, Allocation of Profits, Percentage			65.00%
Betaine Anhydrous [Member] | Obligation Based on Commercial Success [Member]
Other Commitment			$ 1,000
FDA-Approved ANDA For Nitisinone [Member]
Payments to Acquire Marketing Rights											$ 150
Commitment, Allocation of Profits, Percentage											80.00%
FDA-Approved ANDA For Nitisinone [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member]
Payments to Acquire Marketing Rights											$ 500
PKU GoLike [Member]
Other Commitment									$ 2,000
Commitment, Milestone Fee									$ 500
Royalty on Net Sales of Products, Percent									30.00%
Payments to Acquire Marketing Rights									$ 2,200
Commitment, Milestone One Revenue									4,000
Commitment, Milestone Two Revenue									8,000
Commitment, Milestone Three Revenue									15,000
Commitment, Milestone Four Revenue									$ 20,000
GALZIN [Member]
Payments to Acquire Marketing Rights							$ 7,000
Royalties, Percentage of Net Sales,							10.00%							10.00%
GALZIN [Member] | Inventories [Member]
Payments to Acquire Marketing Rights							$ 200
Increlex [Member]
Other Commitment							2,500							$ 2,500
Payments to Acquire Marketing Rights							22,500
Payments to Acquire Inventory							$ 7,500
Azurity Pharmaceuticals, Inc. (“Azurity”) [Member]
Revenue, Additional Based on Event and Sales-based Milestones Achievements												$ 5,500
Azurity Pharmaceuticals, Inc. (“Azurity”) [Member] | Milestone Method [Member]
Revenues														$ 27,500
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Successful Manufacturing of Registration Batches [Member]
Other Commitment																			$ 450
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member]
Other Commitment																			$ 200
Royalties, Percentage of Net Sales,																			12.50%
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on First Commercial Sale of Product [Member]
Other Commitment																			$ 250
Royalties, Percentage of Net Sales,																			17.00%
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Topiramate (fka ET-101) [Member]
Accounts Receivable, after Allowance for Credit Loss, Total																					$ 5,000
Liqmeds Worldwide Limited (“LMW”) [Member] | Licensing and Supply Agreement (the “Agreement”) [Member] | Obligation Based on Issuance of Orange-book Listed Patent [Member]
Other Commitment																				$ 650
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member]
Aggregate Value of Licensing Milestone Included in Research and Development Expense															1,000
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)						379,474
Stock Issued During Period, Value, New Issues						$ 1,264
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Obligation Based on Exclusivity Status from FDA [Member]
Other Commitment																						$ 2,500
Diurnal Limited [Member] | License [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member]
Commitment, Milestone Fee						$ 3,500
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member]
Research and Development Expense, Total					$ 500
Royalty on Net Sales of Products, Percent					10.00%
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] | Obligation Based on Development Milestones [Member]
Other Commitment					$ 3,500
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] | Obligation Based on Commercial Success [Member]
Other Commitment					$ 6,000
Dr. Reddy’s [Member] | License [Member]
Revenues													$ 5,000
Sintetica [Member]
Cost of Goods and Services Sold															$ 812
Selenix [Member] | DS-200 [Member]
Revenue, Additional Based on Event and Sales-based Milestones Achievements								$ 6,500
Commitment, Allocation of Profits, Percentage	45.00%	50.00%						45.00%
Proceeds From Up-front Payment								$ 500
AMMTeK [Member] | Amglidia [Member]
Royalties, Percentage of Net Sales,																	14.00%
AMMTeK [Member] | Amglidia [Member] | Maximum [Member]
Other Commitment																	$ 2,350
AMMTeK [Member] | Amglidia [Member] | Receipt of FDA Minutes [Member]
Other Commitment																	500
AMMTeK [Member] | Amglidia [Member] | NDA Acceptance for Review by FDA [Member]
Other Commitment																	550
AMMTeK [Member] | Amglidia [Member] | NDA Approval by the FDA and First Commercial Sale [Member]
Other Commitment																	$ 1,300